Peritoneal Ultrafiltration in Cardio Renal Syndrome.

Exclusion Criteria

• •Recipients of heart transplantation
• •Presence of a mechanical circulatory support device;
• •Hypertrophic obstructive cardiomyopathy;
• •Uncontrolled hypertension with systolic blood pressure ≥ 160 mmHg
• •Severe valvular stenosis;
• •Restrictive cardiomyopathy;
• •Acute coronary syndrome ≤ 6 months before;
• •Active myocarditis
• •Cardiosurgical or Endo-radiological heart procedures ≤ 6 months before
• •Cardiac resynchronization therapy (CRT) implantation or upgrading of pacemaker (PM) or implantable cardioverter defibrillator (ICD) to CRT ≤ 6 months before;
• •Patient with end-stage renal disease, GFR urea clearance + creatinine clearance/2 (\<15 ml/min/1,73 m2 GFR)
• •Any major organ transplant (liver, lung, kidney)
• •Lung embolism ≤ 6 months before;
• •Fibrotic lung disease;
• •Liver Cirrhosis;
• •Absolute contraindication to peritoneal catheter implantation;
• •Logistical and or organizational contra-indication to treatment
• •Active malignancy;
• •Female patients who are pregnant or breast-feeding or who wish to become pregnant during the period of the clinical trial and for three months later
• •Female patients of childbearing age who do not use adequate contracteption.
• •Unwilling and unable to give informed consent;
• •Enrolment in another clinical trial involving medical or device based interventions.
• •Hypersensibility to IMP components.
• •Evidence of any condition that, according to the investigators' judgment, could expose the subject to undue risk and/or prevent the subject from participating in the study procedures and/or potentially afftecting the study quality data.